Why Moderna’s mRNA-1010 flu shot is suddenly in the spotlight

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 07:13. Details in the imprint.

With mRNA-1010, Moderna Inc. is taking its flu ambitions out of the shadow of Covid and into a much harsher light. In late-stage data, the mRNA-based seasonal influenza vaccine has shown strong immune responses in adults, and now a US advisory panel has given it a unanimous thumbs up for older patients.

What mRNA-1010 is aiming for

mRNA-1010 is Moderna’s first stand-alone seasonal influenza vaccine candidate, built on the same mRNA platform that powered its Covid shot but tuned to four WHO-recommended flu strains. The company positions it for adults, including higher-risk groups aged 50 and above.

The idea is simple but bold: replace classic egg-based flu production with a faster, programmable mRNA process, which in theory should adapt more quickly to drifting strains and deliver more consistent immune responses across seasons.

The new data and FDA backing

In a phase 3 trial in adults 50 and older, mRNA-1010 generated higher antibody levels against three of the four influenza strains compared with an approved recombinant vaccine, while matching it on the fourth strain according to Moderna’s late-stage readout.

That dossier convinced the US FDA’s Vaccines and Related Biological Products Advisory Committee, which voted 9-0 that the benefits of mRNA-1010 outweigh its risks for preventing influenza in adults 50 to 64 years and those 65 and older.

How it feels from a patient perspective

On paper, the experience should feel familiar to anyone used to annual flu shots. A single intramuscular injection, similar injection volume, the usual sore arm, chills or fatigue in the first one or two days, based on the safety profile shared so far.

Where it may differ is timing and expectations. If approved, doctors could talk about a flu vaccine that lives in the same modern category as Covid boosters, with patients expecting a more tailored, data-driven update each season rather than a quiet, unchanged ritual.

Strengths, weaknesses, open questions

Strength-wise, the immunogenicity data give Moderna a convincing story in older adults, the group that drives most serious flu complications and hospitalizations. The mRNA platform also dovetails with Covid booster logistics, which many health systems are still fine-tuning.

On the downside, safety will be watched closely. Regulators and clinicians remember the higher reactogenicity of first-generation Covid mRNA vaccines, and any signal beyond the usual short-lived reactions would attract attention once the shot is used in millions of older patients.

Position in Moderna’s broader pipeline

mRNA-1010 is one of several respiratory candidates Moderna is pushing, alongside combination shots that pair influenza with Covid and RSV. The company has been explicit that respiratory vaccines are meant to underpin its revenue base as Covid demand normalizes.

For healthcare systems, the pitch is about simplification. In a later step, a combined mRNA respiratory shot could mean fewer appointments, one needle stick instead of several, and more consistent uptake in vulnerable groups who currently skip at least one recommended vaccine every season.

Where and when patients might see it

If the FDA follows the panel’s recommendation and grants approval, mRNA-1010 would first roll out in the United States through pharmacies, clinics and larger healthcare providers as a prescription vaccine. European and other regulatory submissions would be expected afterwards.

For now, there is no broad commercial availability in Germany, and reimbursement discussions with health insurers would likely follow only after a formal EMA assessment. Until then, mRNA-1010 remains an American story, with global ambitions sketched but not yet realized.

Context for investors and the stock

For Moderna, every positive development around mRNA-1010 helps support the narrative of a diversified vaccine company rather than a one-product Covid story. Respiratory vaccines like this one sit at the core of the company’s medium-term guidance.

Shares of Moderna Inc. (US60770K1034) trade on Nasdaq in New York in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.